The global next-generation sequencing (NGS) market is expected to grow at a CAGR of 16.2% from 2019 to reach $10.35 billion by 2025.
The field of genomics has surpassed expectations over the past three decades due to massive changes in technology that allowed researchers to interrogate larger pieces of the human genome. Next Generation Sequencing (NGS) is one such massively parallel or deep sequencing technology that helps in the identification of sequence of nucleotides in DNA/RNA. Due to its high-throughput production, efficient instrument run, and lower cost compared to the traditional Sanger first-generation sequencing method, NGS is highly preferred for large-scale genomic and transcriptomic sequencing.
Here are the top 10 companies operating in Next Generation Sequencing Market-
Incorporated in 1998 and headquartered at California, U.S.; Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The company’s product portfolio includes integrated sequencing and microarray systems, consumables, and analysis tools, which are designed to accelerate and simplify genetic analysis. The company operates through two business segments namely Core Illumina and Consolidated VIEs (which includes operations Helix and GRAIL). The company offers next generation sequencing products through its core Illumina business segment.
With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Some of the major subsidiaries of the company include Conexio Genomics Pty Ltd (Australia) Illumina AB (Sweden), Edico Genome Inc. (U.S.), NextBio (U.S.), and GenoLogics Life Science Software Inc. (Canada).
Agilent Technologies, Inc.
Incorporated in 1999 and headquartered at Santa Clara, California, U.S.; Agilent Technologies, Inc., offers products in life sciences, diagnostics, and applied chemical markets. The company operates through three business segments- life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The company provides next generation sequencing products under diagnostics and genomics business segment. The company’s diagnostics and genomics business segment include genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses.
The company has its major presence across U.S. and China and has indirect presence in other parts of the world (which includes Asia-Pacific and Rest of Europe) through their distribution channel. The company sells its products mainly through direct sales. It also sells its products through distributors, resellers, and e-commerce services. The major subsidiaries of the company include Agilent Technologies Korea Ltd (South Korea), Agilent Technologies UK ltd (U.K.), LaserGen, Inc. (U.S.), and Seahorse Biosciences (U.S.), among others.
Bio-Rad Laboratories, Inc.
Founded in 1952 and headquartered at Hercules, California, U.S.; Bio-Rad Laboratories, Inc. is engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications. The products and solutions of the company are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as cells, bacteria, antibodies, proteins, and nucleic acids. The company operates through two business segments namely, Life Science and Clinical Diagnostics. The company provides next generation sequencing under Life Science business segment.
The company has strong presence in U.S. and other geographies including Europe, Pacific Rim, Latin America, and Canada. The company also has direct distribution channels in over 35 countries through subsidiaries, distributors and agents. The principal manufacturing and research facilities of the company for life sciences segment is located at California, Singapore, and England.
Thermo Fisher Scientific Inc.
Founded in 2006 and headquartered at Waltham, Massachusetts, U.S.; Thermo Fisher Scientific Inc. is engaged in providing analytical instruments; equipment; reagents & consumables; and software & services – for research manufacturing, analysis, discovery, and diagnostic applications. Company’s premier brands include – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. The company operates through four business segments namely Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics. The company provides next generation sequencing products under the Life Sciences Solution business segment.
The company has strong presence in the U.S. and China and offers their products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors in other geographies.
Incorporated in 1984 and headquartered at Venlo, Netherlands; Qiagen N.V. is engaged in transforming biological samples into molecular insights. QIAGEN N.V. provides its workflow to customers in molecular diagnostics, assay technologies, bioinformatics and automation systems. The company offers more than 500 core consumable products (sample and assay kits); as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The company’s bioinformatics solutions connect laboratory workflows and process extensive amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action. It supports more than 500,000 customers worldwide across molecular diagnostics, applied testing, pharma, and academia sectors.
With its subsidiaries and strong network of distribution, the company markets in products in 130 countries. The company has manufacturing facilities in Germany, U.S., and China that provides products directly to customers and also to Qiagen subsidiaries in other countries. The major subsidiaries of the company include Qiagen Ltd (London), Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen Hamburg GmbH (Germany), and more.
A report into the projected growth of the current Next Generation Sequencing by Meticulous Research® has produced some incredible forecasts for the industry. By 2025, it’s expected to have grown at a CAGR of 16.2%, reaching over $10.35 billion.
Founded in 1947 and headquartered at Waltham, Massachusetts, U.S.; PerkinElmer, Inc. is engaged in providing products & services and solutions for the diagnostics, food, environmental, industrial, life sciences research and applied markets. The company operates through two business segments namely Discovery & Analytical Solutions, and Diagnostics. The company provides next generation sequencing products through Diagnostics business segment. Under this segment, the company offers instruments, reagents, assay platforms, and software to help in testing and screening of genetic abnormalities. The company serves wide array of customers, which include hospitals, medical labs, clinicians, and, medical research professionals.
The company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the company has no direct sales force. The company has its presence across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Some of the subsidiaries of the company are PerkinElmer Genetics, Inc. (U.S.), PerkinElmer NV (Belgium), PerkinElmer do Brasil Ltda. (Brazil), among many others.
F.Hoffmann-La Roche AG
Founded in 1896 and headquartered at Basel, Switzerland; F. Hoffmann-La Roche AG is a pioneer in healthcare industry. The company operates through two major business segments namely, pharmaceuticals and diagnostics which are focused on advancing science to improve people’s lives. Pharmaceutical division is comprised of two business divisions namely, Roche Pharmaceuticals and Chugai, whereas Diagnostic division consists of four business divisions, namely, Centralised and Point of Care Solutions, Diabetes Care, Molecular Diagnostics, and Tissue Diagnostics. These business areas focus on health care applications targeting physicians, hospitals and clinics, and consumers. The company provides next generation sequencing products under diagnostics business segment.
The company has its presence across Switzerland, Germany, United States, Latin America, Japan, Africa, Australia, and Oceania. The major subsidiaries of the company include Roche Diagnostics Corporation (U.S.), Signature Diagnostics GmbH (Germany), among many others.
Founded in 1999 and headquartered at Shenzhen, China; BGI Genomics is a provider of wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions, and other public and private partners. The company offers products for prenatal screening, hereditary cancer screening, testing for rare disease and in aiding precision medicine research and initiatives.
The company offer products in more than 100 countries around the world, which includes 2,000 scientific research institutions and more than 2,300 medical institutions in China. Also, the company offered works with more than 3,000 institutions across Europe, North America and Asia Pacific.
Pacific Biosciences of California, Inc
Incorporated in 2000 and headquartered at California, U.S.; Pacific Biosciences of California, Inc. is a manufacturer of sequencing systems and products to enable de novo genome assembly for identification, annotation and deciphering of genomic structures. The major products of the company include PacBio Sequel I System, Sequel II instrument and the Sequel SMRT Cell 1M, which are capable of sequencing up to approximately one million DNA molecules simultaneously.
The company has principle manufacturing facility at its headquarters Menlo Park, California. The company partners with leading distributors around the globe to increase its geographic presence. The company has its presence in Australia, Brazil, Africa, India, Israel, Italy, Japan, Korea, Mexico, Poland, Spain, and Taiwan through its distributors.
Oxford Nanopore Technologies Ltd
Founded in 2005 and headquartered at England, U.K.; Oxford Nanopore Technologies Ltd is a developer of disruptive, electronic, single-molecule sensing system based on nanopore science. The company provides electronics-based DNA/RNA sequencing technology to perform wide range of biological research applications including large scale human genomics, cancer research, microbiology, plant science and environmental research.
The company’s commercial team serves more than 70 countries including the U.K., the U.S., Singapore, Shanghai, Beijing, Japan, Germany, France, and India.
Popular Mentions: Beckman Coulter, Inc., GenapSys, Inc., New England Biolabs, Inc., PierianDx, and 10X Genomics, Inc
Authoritative Research on the Next Generation Sequencing Market – Global Opportunity Analysis and Industry Forecast (2019-2025)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: